ACM
RARE icon

ADAR1 Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

ADAR1 Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$419K Buy
20,000
+10,000
+100% +$225K 0.02% 216
2025
Q4 		$230K Buy
+10,000
New +$329K 0.02% 227

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ADAR1 Capital Management's RARE Position: Q1 2026 in Review

ADAR1 Capital Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 13,400 shares worth $281K. The stake represents 0.02% of the portfolio and ranks #244 among its holdings. This is a return to the name: ADAR1 Capital Management previously reported a position in RARE as recently as Q3 2025.

ADAR1 Capital Management first reported a position in RARE in Q4 2024 and has held it in 3 quarters since. The position peaked at $337K in Q4 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • ADAR1 Capital Management held 13,400 shares of Ultragenyx Pharmaceutical worth $281K as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new ADAR1 Capital Management position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.02% of ADAR1 Capital Management's portfolio in Q1 2026, its #244 holding.
  • ADAR1 Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 3 quarters since.
  • ADAR1 Capital Management's Ultragenyx Pharmaceutical position peaked at $337K in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.